Core Viewpoint - The announcement from Gilead Sciences-B (01672) regarding positive results from the ASC50 clinical trial has led to a nearly 3% increase in stock price, reflecting investor optimism about the drug's potential in treating autoimmune diseases [1] Group 1: Clinical Trial Results - Gilead announced positive topline results from a Phase I clinical trial (NCT07024602) for ASC50, which was a randomized, double-blind, placebo-controlled study conducted in the United States [1] - The trial involved 46 healthy participants who received varying doses of ASC50 (10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg) or a matching placebo [1] - The study aimed to evaluate the safety, tolerability, pharmacokinetics, and targeted binding characteristics of ASC50 to interleukin-17A (IL-17A) [1] Group 2: Drug Information - ASC50 is an orally administered small molecule IL-17 targeted inhibitor developed by Gilead, which has shown biological validation and commercial potential in treating psoriasis and other autoimmune and inflammatory diseases [1] - ASC50 is classified as a new chemical entity (NCE) and is protected by patents in the U.S. and globally, with patent protection lasting until 2043, excluding potential extensions [1]
港股异动 | 歌礼制药-B(01672)回暖近3% IL-17抑制剂ASC50美国I期研究取得积极顶线结果